ZHENGYE BIOTECHNOLOGY-A (ZYBT) Fundamental Analysis & Valuation

NASDAQ:ZYBT • KYG989MS1016

Current stock price

0.9225 USD
+0.04 (+4.7%)
Last:

This ZYBT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ZYBT Profitability Analysis

1.1 Basic Checks

  • In the past year ZYBT has reported negative net income.
  • ZYBT had a positive operating cash flow in the past year.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

  • With a decent Return On Assets value of -2.05%, ZYBT is doing good in the industry, outperforming 75.39% of the companies in the same industry.
  • ZYBT's Return On Equity of -3.46% is fine compared to the rest of the industry. ZYBT outperforms 79.06% of its industry peers.
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROIC N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 5 10 15

1.3 Margins

  • ZYBT's Profit Margin has declined in the last couple of years.
  • In the last couple of years the Operating Margin of ZYBT has declined.
  • With a decent Gross Margin value of 44.51%, ZYBT is doing good in the industry, outperforming 62.83% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ZYBT has declined.
  • The Profit Margin and Operating Margin are not available for ZYBT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.51%
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ZYBT Health Analysis

2.1 Basic Checks

  • ZYBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ZYBT has about the same amout of shares outstanding than it did 1 year ago.
  • ZYBT has a better debt/assets ratio than last year.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • ZYBT has an Altman-Z score of 1.56. This is a bad value and indicates that ZYBT is not financially healthy and even has some risk of bankruptcy.
  • ZYBT has a Altman-Z score (1.56) which is in line with its industry peers.
  • ZYBT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ZYBT (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC7.52%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • ZYBT has a Current Ratio of 1.49. This is a normal value and indicates that ZYBT is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.49, ZYBT is not doing good in the industry: 75.92% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.10 indicates that ZYBT should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.10, ZYBT is not doing good in the industry: 79.06% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.1
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ZYBT Growth Analysis

3.1 Past

  • The earnings per share for ZYBT have decreased strongly by -123.72% in the last year.
  • Measured over the past years, ZYBT shows a very strong growth in Earnings Per Share. The EPS has been growing by 528.02% on average per year.
  • The Revenue for ZYBT has decreased by -18.89% in the past year. This is quite bad
  • Measured over the past years, ZYBT shows a very strong growth in Revenue. The Revenue has been growing by 854.79% on average per year.
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

Find the best growth stocksShow best growing peers

1

4. ZYBT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZYBT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZYBT indicates a somewhat cheap valuation: ZYBT is cheaper than 79.06% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 25.28
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZYBT Dividend Analysis

5.1 Amount

  • ZYBT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYBT Fundamentals: All Metrics, Ratios and Statistics

ZHENGYE BIOTECHNOLOGY-A

NASDAQ:ZYBT (4/28/2026, 8:06:59 PM)

0.9225

+0.04 (+4.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.49%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap43.72M
Revenue(TTM)248.68M
Net Income(TTM)-10.36M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP-1.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.2
P/FCF N/A
P/OCF 24.08
P/B 1
P/tB 1.08
EV/EBITDA 25.28
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY4.15%
SpS0.77
BVpS0.92
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.51%
FCFM N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.37
Cap/Depr 50.15%
Cap/Sales 5.07%
Interest Coverage N/A
Cash Conversion 97.56%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.1
Altman-Z 1.56
F-Score3
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.24%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A

ZHENGYE BIOTECHNOLOGY-A / ZYBT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY-A (ZYBT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZYBT.


What is the valuation status of ZHENGYE BIOTECHNOLOGY-A (ZYBT) stock?

ChartMill assigns a valuation rating of 1 / 10 to ZHENGYE BIOTECHNOLOGY-A (ZYBT). This can be considered as Overvalued.


How profitable is ZHENGYE BIOTECHNOLOGY-A (ZYBT) stock?

ZHENGYE BIOTECHNOLOGY-A (ZYBT) has a profitability rating of 2 / 10.


Is the dividend of ZHENGYE BIOTECHNOLOGY-A sustainable?

The dividend rating of ZHENGYE BIOTECHNOLOGY-A (ZYBT) is 0 / 10 and the dividend payout ratio is -1.59%.